Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine

Targeted immunotherapy of solid cancers with chimeric antigen receptor (CAR) T cells and immunocytokines are attractive options in that they both rely on the specificity of tumor-targeted antibodies. Since carcinoembryonic antigen (CEA) expression in both colon and breast cancers is correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Seung E., Kujawski, Maciej, J. Yazaki, Paul, Brown, Christine, Shively, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993151/
https://www.ncbi.nlm.nih.gov/pubmed/33796409
http://dx.doi.org/10.1080/2162402X.2021.1899469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993151/
https://www.ncbi.nlm.nih.gov/pubmed/33796409
http://dx.doi.org/10.1080/2162402X.2021.1899469

Ejemplares similares